REGN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Regeneron Pharmaceuticals Inc (REGN) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock shows strong technical indicators, positive analyst sentiment with raised price targets, and promising catalysts in its pipeline. While the recent financial performance has some weaknesses, the long-term growth potential and hedge fund interest outweigh these concerns.
The technical indicators for REGN are bullish. The MACD histogram is positive and expanding, indicating upward momentum. The RSI is neutral at 60.613, and the moving averages are aligned bullishly (SMA_5 > SMA_20 > SMA_200). The stock is trading near its resistance level (R1: 790.342), suggesting potential for further upside.
Analysts have raised price targets significantly, with Guggenheim setting a target of $975 and JPMorgan at $950, citing optimism around the pipeline and Dupixent's performance.
Hedge fund buying has surged by 167% in the last quarter, indicating strong institutional interest.
Upcoming catalysts include FDA decisions and Phase 3 trial data for key drugs like fianlimab and Eylea HD.
Financial performance in Q4 2025 showed a decline in net income (-7.97% YoY) and EPS (-2.72% YoY), which may concern some investors.
Some analysts, like Morgan Stanley, view the stock as lacking immediate catalysts despite its long-term potential.
In Q4 2025, revenue increased by 2.51% YoY to $3.88 billion, but net income dropped by 7.97% YoY to $844.6 million. EPS declined by 2.72% YoY to $7.86, and gross margin fell to 84.95%, down 3.91% YoY. While revenue growth is positive, profitability metrics showed some weakness.
Analysts are broadly positive on REGN, with multiple firms raising price targets and maintaining Buy or Outperform ratings. Guggenheim and JPMorgan highlight the company's strong pipeline and Dupixent's performance as key drivers. However, some firms, like Morgan Stanley, remain cautious, citing a lack of immediate catalysts.
